PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for May 5, 2008 Subscribe to this News Feed    
 

Applied Biosystems & Bio-Rad Gain Gene Expression Profiling Market Share

Dynamic Gene Expression Profiling Market Revealed in Percepta Associates New Gene Expression Profiling Life Science DashboardTM Market Research Report

CARLSBAD, Calif. (Business Wire EON/PRWEB ) May 5, 2008 -- Today Percepta Associates Inc. announced the release of Series Two of its Gene Expression Profiling Life Science DashboardTM market research report. Drawing comparisons to the findings of Series One published in February 2007, Percepta reports measurable shifts in market share within this market.

Perceptas survey of active global life science researchers revealed that Applied Biosystems (NYSE:ABI) and Bio-Rad Laboratories (AMEX:BIO) have enjoyed the greatest gains in overall market share in the largest expression profiling segments. Affymetrix (NASDAQ:AFFX) remains the strong leader in its primary market segment, microarray-based expression profiling, but other companies appear to be making headway. This new Gene Expression Profiling DashboardTM reveals Invitrogen (NASDAQ:IVGN), Agilent Technologies (NYSE:A), and Roche Applied Sciences (VTX:ROG.VX) are among other companies that experienced market share changes in 2007. Contributing to these market dynamics is an increase in nearly all segments in researchers desire to switch gene expression product suppliers for a variety of performance or service reasons.

News Image Product segments analyzed in Series Two of the new Gene Expression Profiling Life Science DashboardTM include:

Microarray-based gene expression analysis

Serial analysis of gene expression (SAGE)

Differential gene expression analysis using multiplex PCR

qRT-PCR analysis using gene specific probes

qRT-PCR analysis using SYBR Green

Northern Blot analysis

Transcriptome studies using tiling arrays (new in Series Two)

Transcriptome studies using short read sequencing (new in Series Two)

Gene expression profiling methods enable the detection and measurement of multiple expressed gene transcripts in a single RNA sample. Continually evolving methods, such as microarray analysis, multiplex PCR and quantitative real-time PCR, are integral to deciphering the molecular mechanisms involved in gene function, biological development and disease progression, and are important tools in the discovery and development of new drug targets and diagnostic biomarkers.

The expression profiling market churn observed in this market research report illustrates how the genomics market will be changing as new technologies are embraced that enable researchers to integrate genetic analysis methods more cost effectively and extract even more information from a single sample. said Scott Provost, Principal at Percepta. The most successful life science market suppliers will monitor the early market indicators, anticipate change and rapidly make the strategic adjustments needed to secure market leadership. The Life Science DashboardTM series was designed to support this process.

To view gene expression profiling market research sample data and questionnaires visit:

http://www.perceptaassociates.com/publications/08_gene_expression_ overview.shtml (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Life Science Dashboards are readily accessible sources of current, segment-specific, market research. Designed and implemented by industry veterans, each dashboard provides key life science market indicators compiled from the survey responses of qualified decision-makers and researchers actively using life science research products.

Unlike other market research reports, Percepta's Dashboards feature an at-a-glance format that provides rapid access to actionable key market indicators in an easy to understand framework, including:

Market size

Market share

Market growth and reaction throughput rates

Customer satisfaction

Propensity to switch

Competitive intensity

Perceived pricing

Top suppliers

Technique usage frequency

Fastest growing techniques

Primary and secondary downstream applications

About Percepta

Founded in 2005 in Carlsbad, California Percepta Associates serves a rapidly growing roster of bioscience clients across North America and Europe. Percepta is a specialized consultancy providing expert market research, strategic business planning, portfolio management, product and corporate branding and marketing communications services. For more information visit www.perceptaassociates.com

Release Summary:

Today Percepta Associates Inc. announced the release of its Gene Expression Profiling Life Science DashboardTM market research report. Percepta reports measurable shifts in market share within this market.

KEYWORDS: Applied Biosystems, gene expression profiling, life science, life science market research, market research

See the original story at: http://eon.businesswire.com/releases/market/expression/prweb916744.htm

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1FbXB0LUZhbHUtUHJvZi1GYWx1LVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION

Percepta Associates Inc.
Mike Klein, 760-597-9236
mklein@perceptaassociates.com

ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move